Diabetic Neuropathy Market accounted for US$ 4.22 billion in 2020 and is estimated to be US$ 9.87 billion by 2030 and is anticipated to register a CAGR of 8.90%. Diabetic neuropathy is a type of nerve damage that can occur if you have diabetes. High blood sugar (glucose) can injure nerves throughout your body. Diabetic neuropathy most often damages nerves in your legs and feet. The condition most often affects the legs and feet. For some people, symptoms are mild. For others, symptoms can be painful, debilitating and even fatal. Symptoms include pain and numbness in the legs. In more severe cases, symptoms include issues with digestion, the bladder and controlling heart rate. Treatment includes managing blood sugar and using medication to control symptoms.
The report " Global Diabetic Neuropathy Market, By Disorder Type (Peripheral Neuropathy, Autonomic Neuropathy, Proximal Neuropathy and Focal Neuropathy), By Treatment Type (Drugs, Analgesic, Antidepressants, Anticonvulsant Drugs, Radiotherapy and Physiotherapy), By Distribution Channel (Hospitals, Clinics, Retail Pharmacy, Online Pharmacy), Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa), Trends, Analysis and Forecast till 2030”
Key Highlights:
· In 2021, Affinity Bio Partners Launch Clinical Trials for P.A. Medical Cannabis Patients Suffering From Diabetic Nerve Pain.
· In 2021, the neurostimulation company Nevro has secured a new FDA approval for its chronic pain treatment device, aimed at patients suffering from nerve damage associated with diabetes.
Analyst View:
The rising government initiatives in order to reduce diabetic related disease supports the global diabetic neuropathy market. Increasing number of obesity overall the globe is a major factor that drives the global diabetic neuropathy market. Further, increasing number of cardiovascular disease also supports the growth of target market.
Before purchasing this report, request a sample or make an inquiry by clicking the following link:
https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/2213
Key Market Insights from the report:
The global diabetic neuropathy market accounted for US$ 4.22 billion in 2020 and is estimated to be US$ 9.87 billion by 2030 and is anticipated to register a CAGR of 8.90%. Global Diabetic Neuropathy Market is segmented based on disorder type, treatment type, distribution channel and region.
· By Disorder Type, the market is segmented into Peripheral Neuropathy, Autonomic Neuropathy, Proximal Neuropathy and Focal Neuropathy.
· By Treatment Type, the market is segmented into Drugs, Analgesic, Antidepressants, Anticonvulsant Drugs, Radiotherapy and Physiotherapy.
· By Distribution Channel, the market is segmented into Hospitals, Clinics, Retail Pharmacy, Online Pharmacy.
· By Region, the Global Diabetic Neuropathy Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
Competitive Landscape:
Some of the prominent players operating in the global diabetic neuropathy market include Pfizer Inc., Janssen Pharmaceuticals, Inc., Eli Lilly and Company, ACTAVIS, Cephalon, Inc., MEDA Pharma GmbH & Co. KG, GlaxoSmithKline, NeuroMetrix, Inc, Lupin limited and Glenmark Pharmaceuticals Ltd.
The market provides detailed information regarding the industrial base, productivity, strengths, manufacturers, and recent trends which will help companies enlarge the businesses and promote financial growth. Furthermore, the report exhibits dynamic factors including segments, sub-segments, regional marketplaces, competition, dominant key players, and market forecasts. In addition, the market includes recent collaborations, mergers, acquisitions, and partnerships along with regulatory frameworks across different regions impacting the market trajectory. Recent technological advances and innovations influencing the global market are included in the report.
